Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2014 2
2017 3
2018 4
2019 11
2020 11
2021 5
2022 3
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network.
Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM, Wejse C, Muñoz Torrico M, Duarte R, Alffenaar JW, Schaaf HS, Marais BJ, Cirillo DM, Alagna R, Rendon A, Pontali E, Piubello A, Figueroa J, Ferlazzo G, García-Basteiro A, Centis R, Visca D, D'Ambrosio L, Sotgiu G; members of the Global Tuberculosis Network. Migliori GB, et al. Among authors: piubello a. Int J Infect Dis. 2020 Mar;92S:S15-S25. doi: 10.1016/j.ijid.2020.01.042. Epub 2020 Feb 4. Int J Infect Dis. 2020. PMID: 32032752 Free article. Review.
Multidrug-resistant tuberculosis.
Chiang CY, Van Deun A, Trébucq A, Piubello A, Schwoebel V, Rieder HL. Chiang CY, et al. Among authors: piubello a. Lancet. 2019 Jul 27;394(10195):299. doi: 10.1016/S0140-6736(19)30046-7. Lancet. 2019. PMID: 31354138 No abstract available.
World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward.
Van Deun A, Decroo T, Tahseen S, Trébucq A, Schwoebel V, Ortuno-Gutierrez N, de Jong BC, Rieder HL, Piubello A, Chiang CY. Van Deun A, et al. Among authors: piubello a. Int J Antimicrob Agents. 2020 Jan;55(1):105822. doi: 10.1016/j.ijantimicag.2019.10.003. Epub 2019 Oct 15. Int J Antimicrob Agents. 2020. PMID: 31626907
Safety, effectiveness, and adherence of a short and all-oral treatment regimen for the treatment of rifampicin-resistant tuberculosis in Niger: a study protocol of a pragmatic randomised clinical trial with stratified block randomisation.
Souleymane MB, Decroo T, Soumana A, Maman Lawan I, Gagara-Issoufou A, Halidou-Moussa S, Ortuño-Gutiérrez N, Adehossi E, Mamadou S, Van Deun A, Piubello A. Souleymane MB, et al. Among authors: piubello a. Trials. 2022 Dec 13;23(1):1011. doi: 10.1186/s13063-022-06912-7. Trials. 2022. PMID: 36514153 Free PMC article.
High rate of adverse drug reactions with a novel tuberculosis re-treatment regimen combining triple doses of both isoniazid and rifampicin.
Souleymane MB, Kadri S, Piubello A, Tsoumanis A, Soumana A, Issa H, Amoussa AK, Van Deun A, Lynen L, de Jong BC, Decroo T. Souleymane MB, et al. Among authors: piubello a. Int J Infect Dis. 2023 Aug;133:78-81. doi: 10.1016/j.ijid.2023.05.002. Epub 2023 May 5. Int J Infect Dis. 2023. PMID: 37150352 Free article. Clinical Trial.
QTc and anti-tuberculosis drugs: a perfect storm or a tempest in a teacup? Review of evidence and a risk assessment.
Monedero-Recuero I, Hernando-Marrupe L, Sánchez-Montalvá A, Cox V, Tommasi M, Furin J, Chiang CY, Quelapio M, Koura KG, Trébucq A, Padanilam X, Dravniece G, Piubello A. Monedero-Recuero I, et al. Among authors: piubello a. Int J Tuberc Lung Dis. 2018 Oct 26. doi: 10.5588/ijtld.18.0423. Online ahead of print. Int J Tuberc Lung Dis. 2018. PMID: 30366516
41 results